275 related articles for article (PubMed ID: 28825888)
1. Ten Things You Might Not Know about Iron Oxide Nanoparticles.
Daldrup-Link HE
Radiology; 2017 Sep; 284(3):616-629. PubMed ID: 28825888
[TBL] [Abstract][Full Text] [Related]
2. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?
Neuwelt EA; Hamilton BE; Varallyay CG; Rooney WR; Edelman RD; Jacobs PM; Watnick SG
Kidney Int; 2009 Mar; 75(5):465-74. PubMed ID: 18843256
[TBL] [Abstract][Full Text] [Related]
3. Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging.
Unterweger H; Janko C; Schwarz M; Dézsi L; Urbanics R; Matuszak J; Őrfi E; Fülöp T; Bäuerle T; Szebeni J; Journé C; Boccaccini AR; Alexiou C; Lyer S; Cicha I
Int J Nanomedicine; 2017; 12():5223-5238. PubMed ID: 28769560
[TBL] [Abstract][Full Text] [Related]
4. Pictorial review on abdominal applications of ferumoxytol in MR imaging.
Kordbacheh H; Baliyan V; Parakh A; Wojtkiewicz GR; Hedgire S; Harisinghani MG
Abdom Radiol (NY); 2019 Oct; 44(10):3273-3284. PubMed ID: 31378828
[TBL] [Abstract][Full Text] [Related]
5. Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours.
Neuwelt EA; Várallyay P; Bagó AG; Muldoon LL; Nesbit G; Nixon R
Neuropathol Appl Neurobiol; 2004 Oct; 30(5):456-71. PubMed ID: 15488022
[TBL] [Abstract][Full Text] [Related]
6. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.
Daldrup-Link HE; Theruvath AJ; Rashidi A; Iv M; Majzner RG; Spunt SL; Goodman S; Moseley M
Pediatr Radiol; 2022 Feb; 52(2):354-366. PubMed ID: 34046709
[TBL] [Abstract][Full Text] [Related]
7. Exceedingly small iron oxide nanoparticles as positive MRI contrast agents.
Wei H; Bruns OT; Kaul MG; Hansen EC; Barch M; Wiśniowska A; Chen O; Chen Y; Li N; Okada S; Cordero JM; Heine M; Farrar CT; Montana DM; Adam G; Ittrich H; Jasanoff A; Nielsen P; Bawendi MG
Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2325-2330. PubMed ID: 28193901
[TBL] [Abstract][Full Text] [Related]
8. Ultrasmall superparamagnetic iron-oxide-enhanced MR imaging of normal bone marrow in rodents: original research original research.
Simon GH; Raatschen HJ; Wendland MF; von Vopelius-Feldt J; Fu Y; Chen MH; Daldrup-Link HE
Acad Radiol; 2005 Sep; 12(9):1190-7. PubMed ID: 16099684
[TBL] [Abstract][Full Text] [Related]
9. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients.
Chachuat A; Bonnemain B
Radiologe; 1995 Nov; 35(11 Suppl 2):S274-6. PubMed ID: 8588035
[No Abstract] [Full Text] [Related]
10. Design of iron oxide-based nanoparticles for MRI and magnetic hyperthermia.
Blanco-Andujar C; Walter A; Cotin G; Bordeianu C; Mertz D; Felder-Flesch D; Begin-Colin S
Nanomedicine (Lond); 2016 Jul; 11(14):1889-910. PubMed ID: 27389703
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide.
Herborn CU; Vogt FM; Lauenstein TC; Dirsch O; Corot C; Robert P; Ruehm SG
J Magn Reson Imaging; 2006 Aug; 24(2):388-93. PubMed ID: 16791857
[TBL] [Abstract][Full Text] [Related]
12. Strategies to Reduce the Use of Gadolinium-Based Contrast Agents for Abdominal MRI in Children.
Anderson MA; Harrington SG; Kozak BM; Gee MS
AJR Am J Roentgenol; 2020 May; 214(5):1054-1064. PubMed ID: 32097030
[No Abstract] [Full Text] [Related]
13. Combined use of MR contrast agents for evaluating liver disease.
Ward J; Robinson PJ
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
[TBL] [Abstract][Full Text] [Related]
14. Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.
Yancy AD; Olzinski AR; Hu TC; Lenhard SC; Aravindhan K; Gruver SM; Jacobs PM; Willette RN; Jucker BM
J Magn Reson Imaging; 2005 Apr; 21(4):432-42. PubMed ID: 15779033
[TBL] [Abstract][Full Text] [Related]
15. Liver MR imaging with iron oxides: toward consensus and clinical practice.
Weissleder R
Radiology; 1994 Dec; 193(3):593-5. PubMed ID: 7972790
[No Abstract] [Full Text] [Related]
16. [Current status of the clinical development of MR contrast media].
Laniado M; Kopp AF
Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
[TBL] [Abstract][Full Text] [Related]
17. Do we really need new contrast agents for MR-mammography?
Rachetta E; Spinelli R; Martincich L
Eur J Radiol; 2012 Sep; 81 Suppl 1():S127-8. PubMed ID: 23083558
[No Abstract] [Full Text] [Related]
18. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
Mukundan S; Steigner ML; Hsiao LL; Malek SK; Tullius SG; Chin MS; Siedlecki AM
Am J Kidney Dis; 2016 Jun; 67(6):984-8. PubMed ID: 26786296
[TBL] [Abstract][Full Text] [Related]
19. Low-Molecular-Weight Iron Chelates May Be an Alternative to Gadolinium-based Contrast Agents for T1-weighted Contrast-enhanced MR Imaging.
Boehm-Sturm P; Haeckel A; Hauptmann R; Mueller S; Kuhl CK; Schellenberger EA
Radiology; 2018 Feb; 286(2):537-546. PubMed ID: 28880786
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging.
Müller K; Skepper JN; Tang TY; Graves MJ; Patterson AJ; Corot C; Lancelot E; Thompson PW; Brown AP; Gillard JH
Biomaterials; 2008 Jun; 29(17):2656-62. PubMed ID: 18377983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
